10 research outputs found
FORMULATION AND CHARACTERIZATION OF SUSTAINED RELEASE MATRIX TABLETS OF IVABRADINE USING 32 FULL FACTORIAL DESIGN
Objective: Ivabradine (IB) is anti-Ischemic drug and used for the symptomatic management of stable angina pectoris. IB acts by reducing the heart rate in a mechanism different from beta blockers and calcium channel blockers, two commonly prescribed anti-anginal drugs. IB has a short biological half-life and the dose of 5/7.5 mg twice a day. In this present study, an attempt has been made to prepare sustained release tablet of IB to achieve the desired drug release.Methods: The sustained release polymers, hydroxypropyl methylcellulose K100M (HPMC K100M), guar gum (GG) and xanthan gum (XG) were taken for the preliminary trail from which guar gum and xanthan gum had shown better drug release. Initially, drug-excipients compatibility studies were carried out by using Fourier transformed infrared spectroscopy (FTIR) and Differential Scanning Calorimetry (DSC) which showed no interaction between drug and excipients. Tablets were prepared by wet granulation technique and evaluated for pre-compression and post-compression parameters.Results: 32 full factorial design was applied to achieve controlled drug release up to 24 h. The concentration of GG (X1) and XG (X2) were selected as independent variables and the % CDR at 2 h. (Y1) and 18 h. (Y2) were taken as dependent variables. In vitro drug release study revealed that as the amount of polymers increased, % CDR decreased.Conclusion: Contour as well as response surface plots were constructed to show the effect of X1 and X2 on % CDR and predicted at the concentration of independent variables X1 (10 mg) and X2 (10 mg) for a maximized response. The optimized batch (O1) was kept for stability study at 40±2 °C/75±5 %RH for a period of 6mo according to ICH guidelines and found to be stable
Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure.
Endothelial dysfunction is a critical factor in many cardiovascular diseases, including hypertension. Although lipid signaling has been implicated in endothelial dysfunction and cardiovascular disease, specific molecular mechanisms are poorly understood. Here we report that Nogo-B, a membrane protein of the endoplasmic reticulum, regulates endothelial sphingolipid biosynthesis with direct effects on vascular function and blood pressure. Nogo-B inhibits serine palmitoyltransferase, the rate-limiting enzyme of the de novo sphingolipid biosynthetic pathway, thereby controlling production of endothelial sphingosine 1-phosphate and autocrine, G protein-coupled receptor-dependent signaling by this metabolite. Mice lacking Nogo-B either systemically or specifically in endothelial cells are hypotensive, resistant to angiotensin II-induced hypertension and have preserved endothelial function and nitric oxide release. In mice that lack Nogo-B, pharmacological inhibition of serine palmitoyltransferase with myriocin reinstates endothelial dysfunction and angiotensin II-induced hypertension. Our study identifies Nogo-B as a key inhibitor of local sphingolipid synthesis and shows that autocrine sphingolipid signaling within the endothelium is critical for vascular function and blood pressure homeostasis
Aggregating Data for Computational Toxicology Applications: The U.S. Environmental Protection Agency (EPA) Aggregated Computational Toxicology Resource (ACToR) System
Computational toxicology combines data from high-throughput test methods, chemical structure analyses and other biological domains (e.g., genes, proteins, cells, tissues) with the goals of predicting and understanding the underlying mechanistic causes of chemical toxicity and for predicting toxicity of new chemicals and products. A key feature of such approaches is their reliance on knowledge extracted from large collections of data and data sets in computable formats. The U.S. Environmental Protection Agency (EPA) has developed a large data resource called ACToR (Aggregated Computational Toxicology Resource) to support these data-intensive efforts. ACToR comprises four main repositories: core ACToR (chemical identifiers and structures, and summary data on hazard, exposure, use, and other domains), ToxRefDB (Toxicity Reference Database, a compilation of detailed in vivo toxicity data from guideline studies), ExpoCastDB (detailed human exposure data from observational studies of selected chemicals), and ToxCastDB (data from high-throughput screening programs, including links to underlying biological information related to genes and pathways). The EPA DSSTox (Distributed Structure-Searchable Toxicity) program provides expert-reviewed chemical structures and associated information for these and other high-interest public inventories. Overall, the ACToR system contains information on about 400,000 chemicals from 1100 different sources. The entire system is built using open source tools and is freely available to download. This review describes the organization of the data repository and provides selected examples of use cases
Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays
Understanding potential health risks
is a significant challenge
due to the large numbers of diverse chemicals with poorly characterized
exposures and mechanisms of toxicities. The present study analyzes
976 chemicals (including failed pharmaceuticals, alternative plasticizers,
food additives, and pesticides) in Phases I and II of the U.S. EPA’s
ToxCast project across 331 cell-free enzymatic and ligand-binding
high-throughput screening (HTS) assays. Half-maximal activity concentrations
(AC50) were identified for 729 chemicals in 256 assays (7,135 chemical–assay
pairs). Some of the most commonly affected assays were CYPs (CYP2C9
and CYP2C19), transporters (mitochondrial TSPO, norepinephrine, and
dopaminergic), and GPCRs (aminergic). Heavy metals, surfactants, and
dithiocarbamate fungicides showed promiscuous but distinctly different
patterns of activity, whereas many of the pharmaceutical compounds
showed promiscuous activity across GPCRs. Literature analysis confirmed
>50% of the activities for the most potent chemical–assay
pairs
(54) but also revealed 10 missed interactions. Twenty-two chemicals
with known estrogenic activity were correctly identified for the majority
(77%), missing only the weaker interactions. In many cases, novel
findings for previously unreported chemical–target combinations
clustered with known chemical–target interactions. Results
from this large inventory of chemical–biological interactions
can inform read-across methods as well as link potential targets to
molecular initiating events in adverse outcome pathways for diverse
toxicities
Profiling 976 ToxCast Chemicals across 331 Enzymatic and Receptor Signaling Assays
Understanding potential health risks
is a significant challenge
due to the large numbers of diverse chemicals with poorly characterized
exposures and mechanisms of toxicities. The present study analyzes
976 chemicals (including failed pharmaceuticals, alternative plasticizers,
food additives, and pesticides) in Phases I and II of the U.S. EPA’s
ToxCast project across 331 cell-free enzymatic and ligand-binding
high-throughput screening (HTS) assays. Half-maximal activity concentrations
(AC50) were identified for 729 chemicals in 256 assays (7,135 chemical–assay
pairs). Some of the most commonly affected assays were CYPs (CYP2C9
and CYP2C19), transporters (mitochondrial TSPO, norepinephrine, and
dopaminergic), and GPCRs (aminergic). Heavy metals, surfactants, and
dithiocarbamate fungicides showed promiscuous but distinctly different
patterns of activity, whereas many of the pharmaceutical compounds
showed promiscuous activity across GPCRs. Literature analysis confirmed
>50% of the activities for the most potent chemical–assay
pairs
(54) but also revealed 10 missed interactions. Twenty-two chemicals
with known estrogenic activity were correctly identified for the majority
(77%), missing only the weaker interactions. In many cases, novel
findings for previously unreported chemical–target combinations
clustered with known chemical–target interactions. Results
from this large inventory of chemical–biological interactions
can inform read-across methods as well as link potential targets to
molecular initiating events in adverse outcome pathways for diverse
toxicities
Aggregating Data for Computational Toxicology Applications: The U.S. Environmental Protection Agency (EPA) Aggregated Computational Toxicology Resource (ACToR) System
In Vitro Screening of 1877 Industrial and Consumer Chemicals, Pesticides, and Pharmaceuticals in up to 782 Assays: ToxCast Phase I and II
Presented at the Annual Society of Toxicology meetin